News

Unleashing the power of patriots
Enlarge image

FundingUKFrance

Unleashing the power of patriots

04.09.2012 - The Bioindustry Association suggests to create a fund that allows Britons to invest in innovative small companies in their home region.

When an idea from France is worth considering in the UK it has to be indeed ground-breaking. London-based Bioindustry Association (BIA) published on 3 September a new report that proposes the creation of a so-called „Citizen’s Innovation Fund“ (CIF). The concept is based on the French „Fonds Communs de Placements dans l’Innovation“ (FCPI) that has raised over €6bn since 1997. The basic idea is to fuel funding of small companies by offering investors tax advantages that, according to BIA Chief Executive Officer Steve Bates, „would allow members of the public to put up to £15,000 a year into a fund for dragons’ den-style experts to invest in innovative companies – with a tax break if they keep their money invested for five years.“ By investing in local enterprises, the CIFs would improve the British public’s engagement in the economic development of their homeland.

The BIA estimates that £300m a year could be unlocked. The money would allow the companies to grow faster and pay taxes sooner than otherwise possible. The government’s expenditures would be levelled within three years and as a side effect over 1,500 new jobs could be created.

http://www.european-biotechnology-news.com/news/news/2012-03/unleashing-the-power-of-patriots.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • KAROLINSKA (S)10.80 SEK3.85%

FLOP

  • THERAMETRICS (CH)0.06 CHF-14.29%
  • SCANCELL HOLDINGS (UK)27.10 GBP-10.41%
  • ALMIRALL (E)16.66 EUR-8.16%

TOP

  • PROTHENA PLC (IE)49.60 USD24.2%
  • DBV Technologies (F)52.00 EUR22.1%
  • VERONA PHARMA (UK)4.92 GBP15.8%

FLOP

  • SCANCELL HOLDINGS (UK)27.10 GBP-29.2%
  • OREXO (S)68.50 SEK-24.1%
  • NORDIC NANOVECTOR (N)27.00 NOK-23.3%

TOP

  • ADOCIA (F)64.00 EUR364.8%
  • 4SC (D)4.52 EUR352.0%
  • WILEX (D)3.69 EUR350.0%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.75 SEK-69.8%
  • NEOVACS (F)1.11 EUR-67.3%

No liability assumed, Date: 30.06.2015